DNA Script Company Profile
DNA Script, founded in 2014 and headquartered in Paris, is a private biotechnology company with 132 employees that develops innovative enzymatic DNA printer technology for rapid synthetic nucleic acid production, has raised $299 million from 35 investors including recent $4.7M later-stage VC funding in 2025, holds a patent portfolio of 307 documents with 112 granted, and aims to accelerate genomics research and therapeutic development.
Company Overview
DNA Script is a developer of DNA printer technology designed to print synthetic nucleic acids for genomics and molecular biology applications. The company's technology features a novel biochemical process for nucleic acid synthesis based on the use of efficient enzymes, enabling rapid production of important genomic experimental precursors such as oligonucleotides. This allows researchers to accelerate their experiments and the development of new therapeutics.
- Year Founded: 2014
- Status: Private
- Employees: 132 (as of 2026)
- Primary Industry: Biotechnology
- Other Industries: Healthcare Technology Systems
- Headquarters: 67 avenue de Fontainebleau, Le Kremlin-Bicêtre, 94270 Paris, France
- Website: www.dnascript.com
Financing and Funding
- Latest Deal Type: Later Stage VC
- Latest Deal Amount: $4.7M (February 2025)
- Total Funding Raised: $299M
- Number of Investors: 35
Selected Funding Rounds
- Later Stage VC: $4.7M (Feb 2025)
- Accelerator/Incubator: (May 2024)
- Later Stage VC: (Jan 2024)
- Later Stage VC (Series C): (Jan 2022)
- Later Stage VC (Series B): (Jul 2020)
- Grant: $3.05M (Feb 2018)
Cap Table (Selected)
- ADP 2016: 58,140 shares, Par Value $0.113080, Issue Price $48.62, Liquidation Pref. Multiple 1x, % Owned 7.47%
- Ordinary: 3,489 shares, Par Value $0.113080, Issue Price $48.62, Liquidation Pref. Multiple 1x, % Owned 0.45%
Patent Portfolio
- Total Documents (Applications and Grants): 307
- Granted: 112
- Pending: 96
Recent Patent Activity (Selected)
- WO-2026017834-A1: Inkjet-assisted enzymatic nucleic acid synthesis and cleavage (Pending, 19-Jul-2024)
- WO-2026008711-A2/A3: Filtering device and method for polynucleotide enzymatic synthesis (Pending, 02-Jul-2024)
- WO-2026008717-A2/A3: Method for enzymatic synthesis of polynucleotides (Pending, 02-Jul-2024)
Investors (Selected)
- Coalition for Epidemic Preparedness Innovations (Impact Investing)
- La French Tech (Accelerator/Incubator)
- Hedonova (Hedge Fund)
- Alexandria Venture Investments (Venture Capital)
- ArrowMark Partners (Asset Manager)
Competitors (Selected)
- Evonetix (Venture Capital-Backed, Cambridge, United Kingdom)
- Nuclera (Venture Capital-Backed, Cambridge, United Kingdom)
- Oxford Nanopore Technologies (Formerly VC-backed, Oxford, United Kingdom)
- Integrated DNA Technologies (Formerly PE-Backed, Coralville, IA)
- Eurofins Genomics Europe Shared Services (Corporation, Ebersberg, Germany)
Frequently Asked Questions
When was DNA Script founded?
DNA Script was founded in 2014.
Where is DNA Script headquartered?
DNA Script is headquartered in Paris, France.
What is the size of DNA Script?
DNA Script has 132 total employees.
What industry is DNA Script in?
DNA Script’s primary industry is Biotechnology.
Is DNA Script a private or public company?
DNA Script is a private company.
How much funding has DNA Script raised over time?
DNA Script has raised $299M.
Who are DNA Script’s investors?
Coalition for Epidemic Preparedness Innovations, La French Tech, Hedonova, Alexandria Venture Investments, and ArrowMark Partners are among the 35 investors who have invested in DNA Script.
Who are DNA Script’s competitors?
Evonetix, Nuclera, Oxford Nanopore Technologies, Integrated DNA Technologies, and Eurofins Genomics Europe Shared Services are some of the 24 competitors of DNA Script.